Immediate Release | 24 March 2025 |
SHENGUAN HOLDINGS (GROUP) LIMITED
神冠控股（集團）有限公司
（於開曼群島註冊成立的有限公司）
（股份代號：00829）
Shenguan Holdings Announces 2024 Annual Results
Maintaining Market Leadership with Significant Achievements in Diversified Business Expansion
(24 March 2025 - Hong Kong) Shenguan Holdings (Group) Limited ("Shenguan Holdings" or the "Company", Stock Code: 00829.HK) is pleased to announce the consolidated annual results of the Company and its subsidiaries (collectively referred to as the "Group") for the year ended 31 December 2024 (the "Year").
In 2024, the Group accelerated the development of the grand health industry under the "Three Developments and One Core" strategy, the Group has successfully launched six series of new products of collagen sausage casings, to further consolidate its leading position in the collagen sausage casings market. At the same time, the Group intensifies its expansion in three major industries, namely collagen food products, collagen skincare products and collagen medical biomaterials. During the year, the Group recorded revenue of approximately RMB1,016.8 million. In the Prior Year, there was an after-tax gain of approximately RMB29.8 million in respect of other gains on the assignment of marketing authorisations for pharmaceutical products while there was no similar gain in the Year and a decrease in revenue of approximately 8.4%, the profit attributable to owners of the parent decreased by only approximately 14.7% to approximately RMB26.7 million for the Year from approximately RMB31.2 million for the Prior Year as a result of the improvement in the gross profit margin, favourable sales of medical collagen raw materials and stringent control of operating expenses in the Year. However, if the above other gains on the assignment of marketing authorisations for pharmaceutical products were excluded, the profit attributable to owners of the parent for the Prior Year would be approximately RMB1.4 million, which in fact represented a significant increase for the Year.
Collagen Sausage Casings: New Product Series Garner Unanimous Customer Praise and Standardised Management Continuously Improved
During the Year, the Group successfully developed and launched six new products of the collagen sausage casings series, namely "fried", "crispy", "fresh", "tender",
1
"bright" and "colorful". The new products earned unanimous customer praise, laying a solid foundation for promoting the comprehensive upgrade of collagen sausage casings products and covering market needs.
To cope with the launch of new products, the Group also constantly strengthens and improves its production capacity. The plan of production capacity expansion formulated by the Group has basically been achieved, with the production capacity of collagen sausage casings reaching 7 billion metres.
Other Products: Persistent Innovation Achieves Significant Progress in Research, Development and Market Penetration.
For the research and development of collagen food products, the Group launched new products such as "Bo Bo Chicken (缽缽雞)" and "Beef Tripe (牛西肚)", which were well received by the market. In addition, the Group upgraded its products such as "ready-to-eat beef tendon", "collagen brown sugar ginger drink", "collagen oat drinks" and "collagen oat porridge', with the packaging and taste catering to the needs of consumers.
For the research and development of collagen skincare products, the Group launched a new series of products this year, enriching the product varieties and gaining a favourable reputation. The development of collagen masks, skin nourishing lotions and multi-effective gel creams under the brands of "Luxianna", "COLL-FULL", "Collagen Family" and "coll-shine" has been improved and launched in the market gradually.
During the Year, the Group performed particularly well in the collagen medical biomaterials segment, with the endotoxin content of the Group's medical collagen raw materials extracted through its proprietary technology being only 0.01EU/ml, which is better than the FDA's standard of 0.5EU/ml in the USA. The prospects of selling medical collagen raw materials were promising, representing an increase of 542.7% as compared with the Prior Year. Application has been made to the national regulatory authorities for the registration licence of "collagen bone filling biomaterials" as Class
- medical device products, which is pending review and approval. The"oral post-operative medical collagen sponge (口腔術後醫用膠原蛋白海綿)" has passed the ethical review, and will enter the clinical trial stage. The "medical collagen dressing ( 醫用膠原蛋白敷 料)" and "small beauty needle ( 小美 容針 )" are in the process of physical and chemical index testing and animal trial.
The Group remains committed to technological innovation, conducting forward-looking scientific research on collagen technology and delivering promising results. In collaboration with Huazhong University of Science and Technology, the Group co-published a research article titled "Collagen nanofiber-lignin composite sponges with adjustable hierarchical pore structure for efficient low-frequency sound
2
absorption" in Advanced Science Journal, addressing challenges in architectural acoustic materials. Inspired by collagen's acoustic-physiological functions in the human body and lignin's structural properties in plants, the study innovatively combined collagen nanofibres with lignin to successfully develop a collagen nanofibre-lignin composite sponge (a kind of natural building acoustic material with superior acoustic and noise reduction properties, light weight, high mechanical performance and biodegradability). The "Microbial-Modified Lignin Composite Collagen Membrane, Preparation and Application (微生物改性木質素複合膠原蛋白 薄膜、製備與應用)" has been granted a national invention patent, with five other patents currently under review.
Ms. Zhou Yaxian, the Chairman of the Group, said, collagen biopolymer serves as a bridge between biology and materials science. Through modern biotechnological extraction, modification, and synthesis, and driven by scientific breakthroughs and technological innovation, its widespread application has become a focal point in biomaterials research. Collagen-basedmedical biomaterials will progress from fundamental research to a stage of clinical translation and rapid industrialisation. The research and application of collagen as a medical biomaterial are embracing a revolutionary breakthrough.
Looking ahead to 2025, as China continues its efforts to boost consumption, through supply-side structural reforms and various stimulus measures, the collagen casing market is expected to gain further momentum. The Group will focus on ensuring consistent quality across its six collagen sausage casing series, particularly the "fried" and "fresh" series. It will also aim to increase the proportion of high-end casings, promote technical transformation in standardized and intelligent production, and enhance economic benefits and work efficiency. These initiatives will collectively strengthen the Group's comprehensive competitiveness and generate substantial returns for shareholders.
-END-
About Shenguan Holdings (Group) Limited
Shenguan Holdings (Group) Limited (referred to as "Shenguan Holdings" or the "Company", Stock Code: 00829.HK) was established in 1979 and listed on the main board of The Stock Exchange of Hong Kong Limited on 13 October 2009. The Group principally engaged in the manufacture and sale of edible collagen sausage casing products, collagen food products, collagen skin care products and polymer collagen medical biomaterials. From producing the first collagen sausage casings in China to possessing three world-first core technologies, the Group has become a world-class enterprise in collagen sausage casings.
For further details of Shenguan Holdings, please visit the website at http://www.shenguan.com.hk/.
3
This press release is issued on behalf of Shenguan Holdings (Group) Limited by
Wonderful Sky Financial Group Ltd.
For further information, please contact:
Wonderful Sky Financial Group Ltd.
Angie Li & Jason Lai
Tel: (852) 6150 8598 / (852) 9798 0715
Email: po@wsfg.hk
4